A group showed that EGFR-mutated NSCLC cell lines with acquired resistance due to either EGFR p.T790M mutation or MET amplification had increased apoptosis when a PIK3CA inhibitor plus a MEK pathway inhibitor were used simultaneously. Here, MET is linked to non-small cell lung carcinoma.